International Niemann–Pick Disease Alliance
Orphazyme US Investor news ...
We are pleased to share the latest update from Cyclo Therapeutics entitled “Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021”:
We are pleased to share the following article “A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia” which describes the collaborative development of an innovative...
Sometimes in such a big organisation as the INPDA, our various member groups can be overshadowed, but we want to show just how important each and every member group is in making the INPDA work. In the INPDA Spotlight this...
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Gainesville, FL – (Businesswire) – 05 January 2021 – Cyclo Therapeutics, Inc. (NasdaqCM:CYTH and CYTHW), a clinical stage biotechnology company...
Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announced today the U.S. Food and Drug Administration (FDA) has extended the...
The INPDA Central Office is winding down for the festive break, and is set to reopen again on Monday the 4th January 2021. To mark the end of this year we are pleased to share the following message from...
12 December 2020 Orphazyme Statement to the NPC Community Dear Global Community of NPC Patients, Families and Collaborators: You may have seen the news announced on 10 December that Kim Stratton has decided to resign as CEO of Orphazyme...
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Gainesville, FL – (Businesswire) –December 9, 2020 – Cyclo Therapeutics, Inc. (“Cyclo Therapeutics” or the “Company”) (NasdaqCM:CYTH, CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment...
The INPDR releases its ambitious Strategic Business Plan 2020 – 2022 setting targets to continue leading edge work and provide impetus for the future. The INPDR, a ground-breaking patient-focused rare disease-specific registry, has announced plans to build on progress...